Brief: FDA Grants Calliditas Therapeutics Accelerated Approval Of TARPEYO
15/12/2021 22:11
Dec 15 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* FDA GRANTS CALLIDITAS THERAPEUTICS ACCELERATED APPROVAL OF
TARPEYO™ (BUDESONIDE) TO REDUCE PROTEINURIA IN IGA NEPHROPATHY
* CALLIDITAS THERAPEUTICS AB - EXPECTED THAT TARPEYO WILL BE
AVAILABLE IN U.S. EARLY IN Q1 OF 2022
* CALLIDITAS THERAPEUTICS AB - IS EXPECTED THAT TARPEYO WILL
BE
AVAILABLE IN U.S. EARLY IN Q1 OF 2022
Source text for Eikon: ID:nPnb1zssfa
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations